The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Geographic atrophy (GA) affects around 5 million individuals worldwide. Genome-wide,
histopathologic, in vitro and animal studies have implicated the activation of the complement …

Background Geographic atrophy is a leading cause of progressive, irreversible vision loss.
The objectives of OAKS and DERBY were to assess the efficacy and safety of …

The complement system is involved in the pathogenesis of several ocular diseases,
providing a rationale for the investigation of complement-targeting therapeutics for these …

Purpose To examine the association between incomplete retinal pigment epithelial and
outer retinal atrophy (iRORA) on OCT imaging and the subsequent risk of developing …

Purpose We evaluate the impact of test target location in assessing rod-mediated dark
adaptation (RMDA) along the transition from normal aging to intermediate age-related …

C3 is a key complement protein, located at the nexus of all complement activation pathways.
Extracellular, tissue, cell‐derived, and intracellular C3 plays critical roles in the immune …

Preservation of photoreceptors beyond areas of retinal pigment epithelium atrophy is a
critical treatment goal in eyes with geographic atrophy (GA) to prevent vision loss. Thus, we …

Effective drug therapy for vitreoretinal disease is a major challenge in the field of
ophthalmology; various protective systems, including anatomical and physiological barriers …

Purpose Geographic atrophy (GA) is a late-stage form of age-related macular degeneration
(AMD) characterized by the expansion of atrophic lesions in the outer retina. There are …